We are revolutionizing intracellular therapeutic development through a non-viral, non-toxic platform for safe and targeted molecular delivery. We focus on solving the huge challenge surrounding targeted intracellular delivery of cancer drugs and other biological therapies. We have developed a novel targeted delivery system that enters the target cell with a fundamentally new mechanism, bypassing endosomes, enhancing the therapeutic efficiency of drugs, and possibly minimizing the side effects to enhance the patient's quality of life.
Cancer always bewilders its victims, leaving them confused and terrified. Conventional treatments are exhausting and often debilitating, significantly reducing the quality of life and the attitude of the patient towards recovery. The main goal of the treatment is not only to cure: it should harm as little as possible. Targeted therapy would allow effective and specific treatment without causing inadvertent damage to healthy tissues.
We specialize in a highly specific and selective intracellular delivery of therapeutics. Striving to improve patient outcomes worldwide and minimize ‘off target’ side effects, we developed a safe and reliable platform to deliver functional biomolecules including nucleotides and proteins to specific cell types. Our mission is to offer safe and affordable treatment solutions for a wide range of diseases from cancer to cystic fibrosis and to improve the quality of life of our patients.
We use our GEENIE platform for drug delivery that allows a highly specific cell-membrane translocation of drugs, and gene editing components, both in vitro and in vivo. This method allows a non-toxic and low immunogenic selective delivery of molecules to specific cell types.
The well-being and health of patients are of our first concern. Compassion and devotion drive us to advance technology and develop the world's safest and most effective drug delivery strategy. Our goal is to become leaders in the next generation therapeutics. We are committed to improving the quality of life of patients worldwide.
We are innovation-driven and patient-inspired to realize a new vision for the delivery of better health outcomes. We challenge one another to achieve our mission creating a culture based on these core values that we share.
Get in touch, partner with us, and use our technology to build your product and revolutionize genome editing therapeutics market!
INDIA
CYGENICA PRIVATE LIMITED
700 NIP, NCL Innovation Park, Dr. Homi Bhabha Road, Pashan, Pune – 411 008, Maharashtra, India
IRELAND
CYGENICA PRIVATE LIMITED
C/O O' Connor Pyne & Co. Limited Unit 4, Joyce House, Barrack Square, Ballincollig, Co. Cork